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Abstract
Title: The Safety and Efficacy in Reversal of Neuromuscular Blockades with Sugammadex
versus Neostigmine
Background: Neuromuscular blockade (NMB) is utilized for skeletal muscle paralysis during
surgery to facilitate mechanical ventilation and prevent undesired patient movement
intraoperatively. The depth of the NMB must be monitored to ensure optimal surgical conditions,
as well as to determine when it is safe to extubate without placing the patient at risk for residual
neuromuscular blockade. A recent survey from the 2017 Anesthesia Patient Safety Foundation
(APSF) has shown that 64-72% of the respondents perceived the incidence of residual NMB to
be only 1-10% (Murphy, 2018). However, Brull and Kopman (2017), determined the incidence
of residual NMB to be 30-50% in the patients admitted to the Post Anesthesia Recovery Unit
(PACU) following surgery. The use of reversal agents can help reduce the incidence of residual
NMB; however, some agents are not effective at all depths of paralysis. Traditionally,
neostigmine has been utilized to antagonize the effects of a neuromuscular blockade elicited by
non-depolarizing agents. In December 2015, the Federal Drug Administration (FDA) approved
sugammadex as a new medication that does not interfere with the acetylcholinesterase receptor
system and ultimately avoids the undesirable side effects commonly seen with traditional
reversal agents.
Purpose: To determine the safety and efficacy of sugammadex and neostigmine on NMB
reversal, a literature review was conducted to provide current, supporting evidence comparing
their use in NMB reversal.
Process: A literature review was conducted utilizing the CINAHL and PubMed databases, all of
which were accessed from the University of North Dakota’s Health Sciences Library. All
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literature was evaluated extensively and applied to this paper or rejected due to substandard
information.
Results: The evidence-based literature verified that sugammadex reverses any level of
neuromuscular blockade within 5 to 10 minutes. The research also supports that sugammadex is
associated with less adverse effects compared to neostigmine.
Implications: Sugammadex can safely be administered to adults with any level of
neuromuscular blockade and efficiently reverses paralysis. Whereas, neostigmine can only
reverse a neuromuscular block that has shown to have some spontaneous recovery before its
administration. Additionally, the literature supports less side-effects with the use of sugammadex
compared to neostigmine.
Keywords: Sugammadex, Neostigmine, Neuromuscular Blockade (NMB), Rocuronium, Train
of Four (TOF), Post-tectonic count (PTC)
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The Safety and Efficacy in Reversal of Neuromuscular Blockades with Sugammadex versus
Neostigmine
Neuromuscular blockade (NMB) is utilized for the purpose of skeletal muscle paralysis
during surgery to facilitate mechanical ventilation and prevent undesired movement by the
patient intraoperatively. Paralysis is achieved by using depolarizing (i.e., succinylcholine) or
nondepolarizing neuromuscular blocking agents. The nondepolarizing agents can be divided into
two categories, the benzylisoquinolones, and the aminosteroidal agents. The benzylisoquinolones
include atracurium and cis-atracurium. Whereas, the steroidal agents include vecuronium and
rocuronium (Nagelhout & Elisha, 2018). The depth of the NMB must be monitored to ensure
optimal surgical conditions, as well as help determine when it is safe to extubate without placing
the patient at risk for residual neuromuscular blockade.
A recent survey from the 2017 Anesthesia Patient Safety Foundation (APSF) has shown
that 64-72% of the respondents perceived the incidence of residual NMB to be only 1-10%
(Murphy, 2018). However, Brull and Kopman (2017), determined the incidence of residual NMB
to be 30-50% in the patients admitted to the PACU following surgery. These patients experience
residual NMB that can lead to various complications, not limited to: “upper airway obstruction
from pharyngeal muscle weakness, hypoxemia, increased risk of aspiration, decreased
ventilatory response to hypoxia, unpleasant muscle weakness, and delay in tracheal extubation”
(Nagelhout & Elisha, 2018, p. 436). All of which, can ultimately lead to an increase in
perioperative morbidity and longer hospital stays (Batistaki et al., 2016).
The use of reversal agents can help reduce the incidence of residual NMB. However,
some agents are not effective at all depths of paralysis. Traditionally, neostigmine has been
utilized to antagonize the effects of neuromuscular blockades elicited by nondepolarizing agents.
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However, it must be used in combination with a muscarinic antagonist, such as glycopyrrolate, to
compensate for the cholinergic side-effects associated with cholinesterase inhibitor
administration. Recently, sugammadex has been approved by the FDA as a new medication that
does not interfere with the acetylcholinesterase receptor system. Thus it avoids the undesirable
muscarinic side effects associated with cholinesterase inhibitors. To determine the safety and
efficacy of sugammadex and neostigmine on NMB reversal, a literature review was conducted to
provide current, supporting evidence comparing their use in reversal of NMBs.
Purpose
The purpose of this independent project is to present a successful case report of an adult
patient undergoing general anesthesia who was safely administered a dose of sugammadex
intraoperatively and monitored for effects postoperatively. Additionally, this independent project
will provide anesthetic providers with evidence-based research regarding the safety and use of
sugammadex compared to neostigmine in reversal of various depths of NMBs.
Case Report
A 157 centimeters, 98.5 kilogram (kg), 73-year-old female presented for a ventral hernia
repair for recurrent ventral hernias. Past medical history included: hypertension (HTN), chronic
kidney disease-stage 3, gastroesophageal reflux disease (GERD), cerebral vascular accident due
to emboli of cerebral artery, former smoker (quit in 1997), osteoarthritis, diverticulosis, iron
deficiency anemia, obesity (BMI 39), sacroiliac (SI) joint pain, dyslipidemia, adjustment
disorder, and neuropathic pain. Past surgical history included gastric bypass, lumbar fusion, and
ventral hernia repairs with no noted complications to anesthesia. She had no known allergies.
Current medications included: ferrous sulfate (325mg), carbamazepine (100mg), omeprazole
(40mg), amlodipine (5mg), metoprolol (50mg), pravastatin (40mg), and aspirin (81mg). As
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needed medications included: acetaminophen, melatonin, and calcium carbonate. She had been
NPO for eight hours. Pre-operative labs included: Hemoglobin 11.1g/dL, Hematocrit 24.8 %,
Platelet count 289 x 103/L, blood glucose 119mg/dL, BUN 47mg/dL, Creatinine 1.17mg/dL,
Sodium 135mEq/L, Potassium 3.8mEq/L, and Chloride 98mEq/L. Using the American Society
of Anesthesiologists (ASA) system, the patient was classified as an ASA level three.
Airway assessment included Mallampati class I, full neck range-of-motion, and adequate
thyromental distance. Preoperative vitals included: blood pressure 100/64 mmHg, heart rate 78
beats per minute, respirations 16 breaths per minute, oxygen saturations of 97% on room air, and
temperature 36.4 degrees Celsius. Auscultation of her heart and lungs revealed clear, bilateral
breaths sounds and regular heart rate and rhythm.
The patient was transported to the operating room (OR) via OR cart. An 18-guage,
peripheral intravenous (IV) line was inserted in the pre-operative care unit, and a lactated ringer
(LR) solution was infusing. A pulse oximetry monitor was applied, and 2-milligrams (mg) of
midazolam IV was administered for anxiolysis and amnesia. Additional standard monitors were
applied to the patient, including five-lead electrocardiogram (EKG), non-invasive blood pressure
cuff, and Bispectral Index (BIS) monitor. The patient was pre-oxygenated with 10-liter (L) of
100% oxygen via face mask with spontaneous ventilation for approximately three minutes.
Induction was initiated with 100-micrograms (mcg) fentanyl IV, 40mg lidocaine IV, 5mg
priming dose of rocuronium IV, and a dexmedetomidine infusion bolus of 0.25mg/kg IV.
Propofol 200mg IV was administered, and cessation of spontaneous respirations was noted along
with loss of eyelash reflex. Tape was carefully placed over the patient’s eyelids to prevent
corneal abrasions, and manual mask ventilation commenced. Forty milligrams of rocuronium IV
was administered for paralysis. Manual mask ventilation was provided for an additional one-
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minute before a Miller 2 laryngoscope was inserted into the patient’s oropharynx, and vocal cord
visualization was confirmed. A size 7.0 endotracheal tube (ETT) was passed through the vocal
cords successfully and the ETT cuff was inflated to minimal occlusive pressure. Endotracheal
placement was confirmed via condensation noted in the ETT with manual breaths, positive endtidal-carbon-dioxide (ETCO2) measurements, and bilateral breath sounds with equal chest rise.
The ETT was then securely taped in place. Supportive ventilation was administered via Drager
ventilator on pressure control ventilation (PCV) mode to ensure adequate tidal volumes,
oxygenation, and ETCO2. The inhalational agent, Desflurane, was started and fresh gas flows
were decreased in increments to provide a 0.8 to 1.0 Minimum Alveolar Concentration (MAC) at
one liter of combined oxygen and air flows. The patient was in the supine position for induction
with her arms at her side. Following induction her arms were padded and abducted less than 90degrees. All other pressure points, lines and tubes were adequately padded for the procedure. A
nasopharyngeal temperature probe was placed in the right nare for continuous temperature
monitoring throughout the surgery. Additional prophylactic medications for nausea and
vomiting, ondansetron 4 mg IV and dexamethasone 4 mg IV, were administered. Two-grams of
cefazolin IV and 5,000-units of heparin IV were also given before the patient was prepped and
draped for surgery. A dexmedetomidine infusion was initated, after the bolus administration, at
0.5 mcg/kg/min IV. Fifty-milligrams of Ketamine IV and 50 mcg of Fentanyl IV were given
prior to incision. Throughout the four hour case, an additional 200 mcg of fentanyl IV, 1 mg
hydromorphone IV, 3,000 milliliters (mL) of LR solution IV, and 500 mL of 5% albumin IV
were administered. Neuromuscular blockade was monitored via Train of Four (TOF) monitor on
the orbicularis oculi muscle. Paralysis was maintained with 10 mg boluses of rocuronium IV
throughout the case to maintain a TOF ratio 2/4.
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At the end of the procedure a final TOF provided 4/4 twitches after a total of 130 mg
rocuronium IV was administered. Based on the amount of neuromuscular blocking agent
administered, it was decided for the patient’s safety to utilize sugammadex 4 mg/kg IV (400 mg)
for adequate neuromuscular reversal. An oral airway was placed, Desflurane was discontinued ,
and high-flow 100% oxygen was administered via pressure control ventilation. Shortly after the
sugammadex administration, spontaneous respirations were noted and the patient was withdrawn
from mechanical ventilation to allow spontaneous breathing. The patient exhibited positive
clinical indicators for extubation (i.e. followed commands, 5-second head lift, adequate tidal
volumes, and purposeful movements). The oropharynx was suctioned and the patient was
extubated to spontaneous mask ventilations and finally to 3L oxygen via nasal cannula. Adequate
air exchange was noted without complication and oxygen saturation (SpO2) was maintained
greater than 94%. The patient was then transferred to the PACU without any complication. The
patient woke up comfortably and denied any pain. Her PACU stay was uneventful, and no
additional opioid or antiemetic medication were required in the PACU. The patient remained
hemodynamically stable throughout her recovery and was successfully transferred to the
inpatient unit for an overnight stay.
Literature Search
To conduct a precise literature search a PICO question was formulated to accurately
identify relevant literature in various search engines. The PICO process is a technique used to
frame and answer health-care related questions to provide evidence-based practice
recommendations and interventions. The PICO acronym stands for Population, Intervention,
Comparison, and Outcome. The following PICO question was formulated: In adult surgical
patients receiving neuromuscular blocking agents, is sugammadex compared to traditional
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acetylcholinesterase inhibitors, such as neostigmine, more effective in reversing neuromuscular
blockades?
The CINAHL database was searched in order to determine whether sugammadex was
superior to traditionally used acetylcholinesterase inhibitors (i.e. neostigmine) in reversing
neuromuscular blockades. The first focused keywords searched were “Neostigmine AND
Sugammadex” which resulted in 104 articles. Then “Safety” was added to the “Neostigmine
AND Sugammadex” search, resulting in 18 articles. Furthermore, the search was limited to,
English articles within the last 10 years (2008-2018), resulting in 16 articles. From the 16 results,
articles were selected based on topic relevancy as well as limited to adult patient studies, which
resulted in 10 studies chosen for initial review.
An additional search of “Neostigmine AND Sugammadex” with “efficacy” produced 19
articles. The search was limited to, English articles within the last 10 years (2008-2018),
resulting in 18 articles. From the 18 articles, multiple studies were duplicates identified with the
initial search and only three additional studies were added for initial review.
Furthermore, the PubMed database was also utilized for the literature search. Using the
advanced search setting the keywords, ‘Neostigmine AND Sugammadex,’ were searched and
resulted in 203 articles. Refining the search by limiting the data to the last five years, English
language, and human subjects, 65 articles were generated. Some articles were duplicates,
identified in the initial CINAHL database search, which were removed from the article selection
and inclusion. Of the 65 PubMed articles an additional 10 articles were selected for initial
review.
Overall, 23 articles were reviewed, however 9 articles were of relevance and selected for
inclusion in the research of the efficacy of sugammadex compared to neostigmine on the reversal
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of neuromuscular blockades. A total of five systematic review/metanalyses and four randomized
control trials were identified and used for the evaluation of sugammadex and neostigmine effects
on neuromuscular blockades.
Terminology
Neuromuscular Transmission
Neuromuscular transmission occurs between motor neurons and muscle cells at the
neuromuscular junction (Butterworth, Mackey, & Wasnick, 2013). A nerve action potential
travels along the nerve and releases Acetylcholine (ACh) into the synaptic cleft (Butterworth et
al., 2013). ACh then travels toward and binds to the nicotinic receptor sites on the muscle
membrane, resulting in depolarization and muscle contraction (Butterworth et al., 2013). Normal
neuromuscular transmission ultimately, depends on ACh binding to nicotinic cholinergic
receptors on motor-end plates of skeletal muscles (Butterworth et al., 2013).
Neuromuscular Blocking Agents
Skeletal muscle relaxation can be produced by multiple influences, one being
neuromuscular blocking agents (muscle relaxants) (Butterworth et al., 2013). There are two
categories of muscle relaxants, depolarizing and nondepolarizing agents (Butterworth et al.,
2013). The single depolarizing agent, succinylcholine, mimics ACh and binds to the receptor
eliciting a continuous depolarization resulting in sustained paralysis for a short duration of time
(Butterworth et al., 2013). Nondepolarizing muscle relaxants act by competing with ACh for the
nicotinic binding sites on skeletal muscles. By competitive inhibition, nondepolarizing agents
occupy the receptor inhibiting depolarization from occurring via ACh, thereby blocking
neuromuscular transmission resulting is muscle paralysis (Butterworth et al., 2013).
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Cholinesterase Inhibitors - Reversal Agent
Reversal of a nondepolarizing neuromuscular blockades can depend on spontaneous
reversal (i.e. gradual diffusion, redistribution, metabolism, and excretion of the drug) or
pharmacological reversal (by direct administration of specific reversal agents) (Butterworth et
al., 2013). Traditionally, NMBs have been reversed indirectly via cholinesterase inhibitors (also
known as acetylcholinesterase inhibitors) (Butterworth et al., 2013). Cholinesterase inhibitors
have the ability to increase the amount of ACh available to compete against the nondepolarizing
agent, ultimately reestablishing normal neuromuscular transmission (Butterworth et al., 2013).
Cholinesterase inhibitors, such as neostigmine, inactivates acetylcholinesterase, thus preventing
the breakdown of acetylcholine into acetate and choline (Butterworth et al., 2013). By binding to
the enzyme, it allows an increase in the concentration of ACh at the junctional cleft (Butterworth
et al., 2013). This rise in ACh, increases the likelihood that ACh will reoccupy the receptor site
that was once occupied by the neuromuscular blocking agent, allowing restoration of normal
neuromuscular function (Butterworth et al., 2013). Neostigmine also allows the ACh within the
cleft to have a longer lifespan because it is not broken down by the enzyme as it normally would
(Butterworth et al., 2013). Ultimately, this allows for more antagonistic dissociation time and
reactivation of the nicotinic receptor site via ACh (Nagelhout & Elisha, 2018). However, in
excessive doses, acetylcholinesterase inhibitors have the ability to potentiate a nondepolarizing
neuromuscular blockade due to the excess ACh available (Butterworth et al., 2013).
Furthermore, ACh can affect more than the nicotinic receptors of skeletal muscles. The excess
ACh can bind to other muscarinic receptors, which are associated with the parasympathomimetic
side effects commonly seen following the administration of neostigmine (Butterworth et al.,
2013). These unwanted side-effects are usually minimized by prior or co-administration of an

SAFETY OF SUGAMMADEX AND NEOSTIGMINE

13

anticholinergic medication, such as atropine or glycopyrrolate (Butterworth et al., 2013). These
anticholinergic medications help prevent the muscarinic side-effects associated the with
cholinesterase inhibitor administration. Normal reversal doses of neostigmine range from 0.030.07 mg/kg IV with an onset of 5-15 minutes and duration of action lasting 45-90 minutes
(Nagelhout & Elisha, 2018).
Reversal Agent- Sugammadex
Until recently, neuromuscular blocking agents, such as rocuronium, vecuronium, and
pancuronium, were commonly pharmacologically reversed via neostigmine (Butterworth et al.,
2013). However, a novel reversal agent, sugammadex, has become available on the United States
pharmaceutical market to selectively reverse rocuronium-induced neuromuscular blockades, and
less selectively the other steroidal neuromuscular blocking agents (Butterworth et al., 2013).
Sugammadex is the first “selective relaxant binding agent” (Nagelhout & Elisha, 2018, p. 163). It
is a modified gamma-cyclodextrin molecule that encapsulates and forms a tight water-soluble
complex in a 1:1 ratio with steroidal neuromuscular blocking agents, including rocuronium,
vecuronium, and pancuronium (Nagelhout & Elisha, 2018). Once the encapsulation occurs there
is no dissociation and the sugammadex-relaxant complex is excreted in the urine (Nagelhout &
Elisha, 2018). This type of reversal mechanism is independent of the neuromuscular blockade
depth (Nagelhout & Elisha, 2018). Thus, a shallow or deep block can be reversed with
appropriate doses (Nagelhout & Elisha, 2018). In contrast to neostigmine, where no amount of
the medication can immediately reverse a block that is so intense there is no response to tetanic
peripheral nerve stimulation (Nagelhout & Elisha, 2018). Sugammadex is most effective against
rocuronium, followed by vecuronium and pancuronium, however it is not effective against the
benzylisoquinolones like neostigmine is (Nagelhout & Elisha, 2018). Dosing of sugammadex
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includes 2 mg/kg IV for moderate neuromuscular block (T2 on TOF), 4 mg/kg IV for a deep
block (1-2 PTC), and 16 mg/kg IV for immediate reversal of an induction dose of rocuronium
(Herring et al., 2017; Merck Connect, 2018).
Neuromuscular Function Monitoring
Monitoring of neuromuscular blockade is a standard of care (Standard V) during any
anesthetic in which muscles relaxant are administered (AANA, 2013). However, it has been
noted that clinicians in the United States are not using any type of monitor to assess level of
paralysis (Nagelhout & Elisha, 2018).
There are several methods available for monitoring the intensity of a neuromuscular
block, but the most commonly used is the visual and tactile responses noted via evoked electrical
stimuli (Nagelhout & Elisha, 2018). Contraction of the adductor muscle of the thumb via
stimulation of the ulnar nerve is the preferred site to determine the level of neuromuscular
blockade (Nagelhout & Elisha, 2018). However, when access to the arm is unavailable,
additional monitoring sites include nerves of the feet and face (Nagelhout & Elisha, 2018).
Paralysis occurs in the following order: the eye muscles, the extremities and trunk of the body
(neck then chest), the abdominal muscles and lastly, the diaphragm (Nagelhout & Elisha, 2018).
Conversely, during recovery it returns in the opposite manner with the eyes being last to fully
recover (Nagelhout & Elisha, 2018). Using the orbicularis oculi muscle may be applicable to
monitor for onset of paralysis because blood and drug distribution to the face muscles mirrors the
distribution to airway (larynx and diaphragm), indicating adequate paralysis for intubation
(Nagelhout & Elisha, 2018). However, for recovery Nagelhout and Elisha (2018) support the
hand to be the best place to measure recovery from NMB, since the hand is more sensitive to
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relaxants than the diaphragm. Thus, if there is recovery in the hand, the upper airway muscles
should be recovered as well (Nagelhout & Elisha, 2018).
Train-of-Four (TOF). Muscle stimulation via Train-of-Four (TOF), Tetany, and PostTetanic Count (PTC) are common methods of measurements of NMB (Nagelhout & Elisha,
2018). The “TOF delivers four separate stimuli every 0.5 seconds at a frequency of 2 Hertz (Hz)
for two seconds” (Nagelhout & Elisha, 2018, p. 142). When comparing the four stimulated
responses they are classified as twitch, T1 up to T4 (Nagelhout & Elisha, 2018). Upon onset of
NMB with a nondepolarizing relaxant there is a progressive reduction of the twitch responses
and strength of the twitch (Nagelhout & Elisha, 2018). This decrease in strength is known as
fade. Fade is referred to the “inability to sustain a response to repetitive nerve stimulation”
(Nagelhout & Elisha, 2018, p. 142). A TOF-ratio compares twitch 4 to twitch 1 and can aid in
approximating the degree of paralysis (Nagelhout & Elisha, 2018). According to Nagelhout and
Elisha, (2018), when the fourth twitch disappears it indicates 75-80% of receptors are blocked
(TOF ratio 3/4). A progressive disappearance of the third twitch correlates with 80-85% block
and when the second twitch is lost (T4, T3, and T2 are absence) reflects 90-95% of NMB is
present (Nagelhout & Elisha, 2018). When there are no twitches visualized or palpated, it
indicates a 100% NMB has been achieved (Nagelhout & Elisha, 2018). Ideally, sufficient
paralysis of 85-95%, is adequate for any procedure (Nagelhout & Elisha, 2018). This correlates
with one to two twitches present during the TOF stimulus (Nagelhout & Elisha, 2018).
Post-Tetanic Count (PTC). The PTC measurement has not been used commonly,
however it is becoming a more utilized test when clinicians have no response to a TOF stimulus
(Nagelhout & Elisha, 2018). The PTC is assessed following a 50-Hz tetanic stimulation for five
seconds followed by a series of single 1 Hz stimulations (Nagelhout & Elisha, 2018). The
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response to the single twitches, correlates with the approximate depth of block and can be
indicative of how long it may take for spontaneous reversal to occur (Nagelhout & Elisha, 2018).
The physiology behind this test is as follows: the single 50Hz tetanus mobilizes excess ACh and
after a three-second pause it is common to see a series of twitches because the extra ACh can
transiently reverse the muscle relaxant (Nagelhout & Elisha, 2018). The more twitches following
tetany correlates with a less intense block (Nagelhout & Elisha, 2018).
Review of the Literature
For neostigmine to be appropriate for administration, adequate spontaneous recovery
must be established (Butterworth et al., 2013). Some evidence of spontaneous recovery, such as a
single twitch of the TOF (T1) should be present before reversal is attempted with
anticholinesterase medication (Butterworth et al., 2013). However, this rule does not apply to
sugammadex. The following research will present the evidence on the safety and efficacy of
reversing neuromuscular blockades with neostigmine and sugammadex.
Moderate Block Reversal
The evaluation of a moderate block is indicated by visual or palpable T1 and T2 twitches
with fade by the TOF stimulator (Carron, Zarantonello, Tellaroli, & Ori, 2016; Herring et al.,
2017; Hristovska, Duch, Allingstrup, & Afshari, 2017; Kaufhold et al., 2016). The primary
findings from the many studies conducted, indicate sugammadex to be faster than neostigmine in
reversing rocuronium-induced NMB (Carron et al., 2016; Herring et al., 2017; Hristovska et al.,
2017; Kaufhold et al., 2016). Hristovska et al., (2017) meta-analysis found sugammadex to be
10.22 minutes, or 6.6 times, faster than neostigmine to produce a TOF ratio of 0.9 or greater
following a moderate rocuronium-neuromuscular blockade. Sugammadex was also seen to
produce faster recovery to baseline neuromuscular function (Carron et al., 2017; Herring et al.,
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2017). Herring et al. (2017) analysis, resulted in 96% and 86% of subjects (respectively for
rocuronium and vecuronium induced NMB) to recover to TOF ratio of 0.9 within 5 minutes. In
contrast, only 16% and 9% (NMB induced via rocuronium and vecuronium, respectively) of the
patients treated with neostigmine recovered to the same TOF ratio within 5 minutes (Herring et
al., 2017). Furthermore, Kaufhold et al. (2016) endorses, lower than the approved, recommended
doses of sugammadex (2 mg/kg IV) may sufficiently reverse a TOF ratio of 0.2 to baseline
neuromuscular function within 5-10 minutes. Whereas, due to the ceiling effect of neostigmine it
was unable to reliably reverse the majority of patients within 10 minutes (Kaufhold et al., 2016).
Kaufhold et al. (2016) recommends to wait until four twitches in the TOF are visible before
using neostigmine for reversal of NMBs due to its unreliable effects. Ultimately, Sugammadex
provides a more reliable recovery associated with a higher TOF value post-extubation, thus
demonstrating sugammadex to be clearly superior over neostigmine in reversing moderate NMB
(Carron et al., 2016; Herring et al., 2017; Hristovska et al., 2017; Kaufhold et al., 2016).
Deep Block Reversal
Deep paralysis is indicated by a PTC of 1 to 4 (Geldner et al., 2012; Herring et al., 2017;
Hristovska et al., 2017; Jones, Caldwell, Brull, & Soto, 2008). The following studies have looked
at the reversal of a deep neuromuscular blockade with 4 mg/kg IV of sugammadex given at 1-2
PTC: Geldner et al., 2012; Herring et al., 2017; Hristovska et al., 2017; Jones et al., 2008;.
Herring et al. (2017) found sugammadex produced an average recovery time of 2.2 minutes and
3.8 minutes following rocuronium and vecuronium induced paralysis, respectively. Within 5
minutes, 95% and 77% (respectively for rocuronium and vecuronium induced NMB) of the
sugammadex group had full recoveries while only 7% of the rocuronium-neostigmine group
recovered within 5 minutes (Herring et al., 2017). Not one person from the vecuronium group
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was able to recover within that 5 minutes following neostigmine administration (Herring et al.,
2017). These results were also seen and supported in Jones et al. (2008) randomized comparison
study and in the meta-analysis conducted by Hristovska et al. (2017). The research established
that the neostigmine group, required 30-60 minutes for majority of its patients to fully recover to
TOF ratio of 0.9 or greater following administration at PTC 1-2 (Hristovska et al., 2017; Jones et
al., 2008). As with the majority of the studies reviewed, Geldner et al. (2012) also found
sugammadex superior to neostigmine despite comparing the reversal of the two medications at
different depths of NMB. The evidence produced in this study supported sugammadex to
produce a more rapid recovery and establishment of normal neuromuscular function with deep
NMB when compared to neostiminge’s reversal of a moderate NMB (Geldner et al., 2012).
Immediate reversal of profound NMB following 1.2 mg/kg IV rocuronium
administration, sugammadex 16 mg/kg IV was found to produce rapid recovery or
neuromuscular function in an average of 1.7 minutes (Herring et al., 2017). Neostigmine was not
studied in this setting due to prior recommendations stating that some indication of spontaneous
recovery must be seen before it can safely be administered (Herring et al., 2017; Kaufhold et al.,
2016).
The faster reversal time associated with sugammadex ultimately allows for earlier
tracheal extubation following maintenance of deep NMB. This can aid in earlier discharge times
from the OR and PACU (Geldner et al., 2012; Jones et al., 2008). All together, sugammadex is
concluded to more rapidly reverse a rocuronium-induced NMB regardless of the depth (Geldner
et al., 2012; Herring et al., 2017; Hristovska et al., 2017; Jones et al., 2008).
General Side-effects/Adverse Effects
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Hemodynamic changes were minimal between the administration of sugammadex
compared to neostigmine throughout all the literature (Geldner et al., 2012; Hristovska et al.,
2017; Jones et al., 2008) Some variable changes in heart rates were noted between the
neostigmine and sugammadex group; however, the changes were immaterial in comparison
(Geldner et al., 2012; Hristovska et al., 2017; Jones et al., 2008). Overall, no statistically
significant findings in regards to hemodynamic changes were concluded throughout the literature
reviewed.
Sugammadex was found to be associated with significantly lower respiratory and
cardiovascular adverse events (AEs), as well as less postoperative weakness (Carron et al., 2016;
Hristovska et al., 2017). There were similar risks found between sugammadex and neostigmine
for pain scores (Carron et al., 2016; Hristovska et al., 2017). Neostigmine was associated with
more respiratory AEs, such as hypoxemia, which can possibly be due to bronchospasm
aggravated by an increased level of respiratory secretions (Carron et al., 2016). Neostigmine has
also been associated with dose-dependent negative effects on the genioglossus muscle and
diaphragmatic function as well as general weakness due to impaired neuromuscular transmission
or inadequate reversal (Carron et al., 2016). Other general AEs were directly related to coadministration of cholinesterase inhibitors and anticholinergic medications (dry mouth, visual
accommodation disorder, or hyperhidrosis) (Carron et al., 2016; Hristovska et al., 2017).
Ultimately, Carron et al. (2016) and Hristovska et al. (2017) found sugammadex provided a more
reliable reversal, with significantly less risk of residual paralysis postoperatively, while also
having a lower adverse effect profile.
Renal Effects
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Sugammadex is renally eliminated thus posing a risk to worsen renal failure. (Herring et
al., 2017). Isik, Palabiyik, Cegin, Goktas, and Kati (2016) and Carron et al. (2016) looked
specifically at the effects sugammadex and neostigmine have on renal biomarkers. They
concluded that both medications minimally affected renal glomerular filtration and tubular
function (Carren et al., 2016; Isik et al., 2016). This marginal reduction in renal clearance
produced only slightly slower recovery times and were not associated with any clinical evidence
of renal dysfunction (Carron et al., 2016; Herring et al., 2017). Additionally, hemodynamic
changes that could potentially affect renal function were also similar between the two groups and
did not lead to further deterioration in renal function (Isik et al., 2016). In regards to severe renal
impairment (i.e. those requiring dialysis), sugammadex is currently not recommended for use
due to the limited data available (Herring et al., 2017). It was concluded that renal function may
be affected by both medications, however, sugammadex has been established to have more
tolerable effects than neostigmine (Carron et al., 2016; Herring et al., 2017; Isik et al., 2016).
Bleeding
Research has shown sugammadex is associated with an increase in Prothrombin Time
(PT) and Activated Partial Thromboplastin Time (aPTT) occurring within 10 minutes following
sugammadex administration (Hristovska et al., 2017; Iwasaki, Renew, Kunisawa, & Brull, 2017).
However, this elevation is seen to resolve within 60 minutes (Hristovska et al., 2017; Iwasaki et
al.,2017). This short-lived increase was concluded to not be associated with any increased
bleeding risk or severity of bleeding (Hristovska et al., 2017, Iwasaki et al., 2017). However, it is
still important to monitor those with coagulopathies or on anticoagulation/thromboprophylaxic
mediations (Herring et al., 2017). One study determined that the transient effect on PT and aPTT
associated with sugammadex was likely attributed to a reaction with phospholipid in the assay
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(Carron, Zarantonello, Lazzarotto, Tellaroli, & Ori, 2017). As a whole, the studies support that
these increases in PT and aPTT are transient and unlikely to be clinically relevant (Carron et al.,
2017; Hristovska et al., 2017; Iwasaki et al., 2017).
Hypersensitivity
Iwasaki et al. (2017) touched on hypersensitivity reactions associated with sugammadex.
The most frequent symptoms of sugammadex-induced anaphylaxis are rash, hypotension, and
tachycardia (Iwasaki et al., 2017). Also, most reactions were triggered within four minutes after
administration. This critical period of hypersensitivity was also confirmed to be within the 5minute time frame following sugammadex injection in the study conducted by Carron et al.
(2017). Thus, it is vital to be vigilant during this critical period to ensure adequate identification
of allergic response are managed in a timely manner.
Discussion
Sugammadex has been shown to decrease the time it takes to achieve a TOF 0.9 or
greater, reflecting the return of normal neuromuscular function. The approved doses of
sugammadex, 2 mg/kg IV for a moderate block or 4 mg/kg IV for a deep block, have been
proven superior to even the largest doses of neostigmine in ensuring adequate and timely reversal
of paralysis. Throughout all the literature, there was a common theme with the use of
neostigmine; it requires some spontaneous recovery from paralysis, such as a single twitch in a
TOF reading, to be eligible for administration in attempts to reverse neuromuscular blockades.
Additionally, some research has shown that it should not be administered until there are 4/4
twitches in the TOF test (Kaufhold et al., 2016). The quicker reversal times associated with
sugammadex has allowed anesthesia providers to maintain a deep level of paralysis for the
entirety of a surgery without risking incomplete recovery or other complications (Geldner et al.,
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2012). This deep paralysis can improve surgical field conditions, such as better views for
laparoscopic cases. It can also allow lower pressures used to create pneumoperitoneum, which
similarly, may provide additional benefits following laparoscopic surgery (Geldner et al., 2012;
Jones et al, 2008). Largely, the research provides support for sugammadex to provide a faster and
more reliable reversal, thus providing a great benefit to its use for patient safety.
As sugammadex has been proven to provide a more reliable reversal of paralysis, it does
not come without risk. Side effects and adverse events can occur with all medications and the
research shows there are less side-effects and risks associated with sugammadex compared to
neostigmine. A significant attribute of sugammadex is that it has been shown to prevent residual
neuromuscular blockade due to it mechanism of action. Its encapsulating method inactivates the
paralytic agent and then together they are excreted from the body (Nagelhout & Elisha, 2018).
Compared to neostigmine, which reverses the neuromuscular blockade via competitive inhibition
(Butterworth et al., 2013). Meaning, it allows more ACh to be available to overcome paralytic
agents from the receptor sites. Consequentially, this can lead to residual neuromuscular blockade
due to paralytic agent remaining in the synaptic cleft; or lead to neuromuscular weakness related
to the excess ACh that has been shown to overstimulate the receptors leading to weakness. Both
of which are suboptimal for patient outcomes following surgery. Overall, more research is
needed to understand the specific side-effects patients experience following surgery with
administration of these reversal agents. Some of the reported side effects can be associated with
other anesthetic drugs administered throughout surgery and may or may not be associated with
the administration of neostigmine or sugammadex. Overall, the most undesirable side-effects
associated with paralysis include residual neuromuscular blockade, generalized weakness, and
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muscarinic effects resulting from the anticholinergic medication administration with
neostigmine. All of which were seen to be minimal in the sugammadex participants’ recovery.
Other important considerations to remember when using sugammadex comes from the
Merck Connect (2018) package insert. It’s important to note that sugammadex can interact with
hormonal contraceptives, posing risk of them becoming less effective (Merck Connect, 2018). It
is imperative to ensure patients are aware of this risk post-operatively after sugammadex has
been administered. It is also important that anesthesia providers are aware that sugammadex is
incompatible with verapamil, ondansetron, and ranitidine (Merck Connect, 2018). Thus, confirm
the infusion line is adequately flushed with approved solutions before sugammadex is coadministered with one of these incompatible agents. In the end, sugammadex has been shown to
be superior to neostigmine in its reversal efficacy and safety profile. Its ability to completely
avoid the muscarinic-associated side-effects linked with traditional reversal agents, creates a
favored choice in anesthetic management for a majority of patients.
Although the clinical benefits of sugammadex outweigh the support for neostigmine,
sugammadex is expensive. The drug patent for sugammadex does not expire until 1/27/2021, and
consequently it is still more expensive than the traditional reversal agents. Currently, small vials
of sugammadex 100 mg/ml in 2ml vial is approximately 117 Euros which equates to roughly
$133 USD (Hristovska, et al., 2017). For a 100 kg patient it would cost between $133 USD to
$266 USD for a 2mg/kg IV or 4mg/kg IV dose. Compared to neostigmine which is
approximately $23 USD for a 10 mL vial of 0.5mg/mL (Drugs.com, 2019a), plus the cost of
glycopyrrolate which is approximately $15 USD for a 5 ml vial of 0.2mg/ml (Drugs, 2019b). For
the 100kg patient, the total cost to administer neostigmine with glycopyrrolate is approximately
$38 USD (0.05mg/kg IV of neostigmine and 0.01mg/kg IV of glycopyrrolate). However, this
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administration comes with a limitation due to the requirement of spontaneous recovery from
NMB before neostigmine can safely and effectively be provided.
Despite being more expensive there are several benefits that can justify the excess cost of
sugammadex. Hristovska et al. (2017) noted sugammadex offers great differences in reversal
time and this extra time has some advantages. One advantage includes, reduced anesthesia time,
which could improve recovery and potentially reduce total costs to the patient and hospital.
Sugammadex can be administered at any stage of a surgical procedure, independent of the block.
Thus, it can reduce patient recovery time perioperatively, which provides staff extra time to work
on alternative activities. Carron et al. (2017) meta-analysis found sugammadex to be associated
with faster OR to PACU discharge, compared to neostigmine (mean difference [MD] for
moderate level blocks was 22.14 minutes and 30.05 minutes for deep NMB). These patients also
had faster PACU to surgical ward times (MD of 16.9 minutes) than the neostigmine participants.
Paton et al. (2010) systematic review of the cost-effectiveness of sugammadex found that the
reduced recovery times associated with sugammadex, economically depends on the ‘value of
each minute’ (Paton et al., 2010, p. 563). It was concluded there is potential for sugammadex to
be cost effective if any time saved due to a faster recovery freed staff to work on productive
activities (Paton et al., 2010). Due to the time saved in the OR by reversing with sugammadex,
those added minutes in turn can be applied to other surgeries, meetings, educational
opportunities, etc. This area of research is hard to conduct due to the various hospital and surgery
structures; however, the potential is there. It largely depends on how effectively that extra time is
being used to understand the net efficiencies.
Conclusion
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Neuromuscular blocking agents induce muscle relaxation which is commonly used
during surgery for facilitating tracheal intubation and providing optimal surgical conditions by
suppressing voluntary skeletal muscle movements. It is important at the end of surgery these
medications can be reversed to allow normal neuromuscular function that is vital to spontaneous
ventilation allowing emergence through anesthesia to preoperative function. Cholinesterase
inhibitors, such as neostigmine have traditionally been the only agents available to counteract the
neuromuscular blockade until recently. Sugammadex is a newer medication that selectively
inhibits neuromuscular blocking agents from allowing paralysis. Sugammadex works by
encapsulating the neuromuscular blocking agent creating a complex that completely inactivates
its ability to produce paralysis. Research has shown sugammadex to completely reverse all levels
of blockades faster than neostigmine. This includes blocks where neostigmine administration is
not favorable due to the depth of the blockade. Overall, the literature supports sugammadex as a
safer and more efficacious medication in the reversal of all depths of neuromuscular blockades.
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